Part A: RNAi for Functional Genomics Screening Conference header



About This Conference:

Cambridge Healthtech Institute’s eleventh annual conference on RNAi for Functional Genomics Screening will cover the latest in the use of RNA interference (RNAi) screens for identifying and validating new drug targets and exploring unknown cellular pathways. It will cover everything from assay design to data analysis for the use of in vitro and in vivo siRNA (small interfering RNA) and shRNA (short hairpin RNA) screens, in a way that will evoke thought-provoking discussions and inspire collaborations.


Emerging Applications for In Vivo Screenin.


FEATURED PRESENTATION: Functional RNAi Screens for Cancer in Mice

Elaine Fuchs, Ph.D., Rebecca C. Lancefield Professor and Investigator, Howard Hughes Medical Institute, Laboratory of Mammalian Cell Biology and Development, The Rockefeller University


In vivo Target Validation with Viral Vectors: Translating In vitro Hits to In vivo Functions

Ki Jeong Lee, Ph.D., Principal Scientist, Genome Analysis Unit, Amgen, Inc.


Exploring RNAi and cDNA Screens for Novel Uses

From Superstar to Washed-Up Delinquent: Is it Time to Abandon RNAi Screening?

Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Institutes for Health

Cell-Based Screening to Empower Human Genetics: Moving from Gene to Genetic Variants

Heiko Runz, M.D., Director of Human Genetics, Merck Research Laboratories

A High Content Screen of an Arrayed cDNA Library for Modulators of Adipogenic Differentiation

Patrick Collins, Ph.D., Senior Scientist, Genome Analysis Unit, Amgen Inc.


Non-Coding RNA Screens: An Unknown Frontier

Functional Dissection of Coding and Long Non-coding Transcripts in Pluripotent Cells

Frank Buchholz, Ph.D., Professor, Medical Systems Biology, UCC, University Hospital and Medical Faculty Carl Gustav Carus, Technische Uuniversitat Dresden

First Screens Using a LncRNA siRNA Library:  Shedding Some Light on the Dark Matter of the Transcriptome

Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences National Institutes of Health

Using ncRNAs to Identify Cancer Cell Vulnerabilities

Alexander Pertsemlidis, Ph.D., Associate Professor, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio


Dissecting Functional Screens: Making the Right Choices

RNAi is Dead, Long Live RNAi: Reinventing the RNAi Screening Workflow

Samuel Hasson, Ph.D., Principal Investigator, Neuroscience, Pfizer, Inc.

RNAi Screens for Identification of Rare Genetic Disease Treatments

Dr. Chris Gibson, CEO, Administration & R&D, Recursion Pharmaceuticals

Phenotypic Screening: Opportunities and Challenges

Jing Li, Ph.D., Director of Genomics and Phenotypic Screening, Merck Research Laboratories

DOT CAG ICON 

green arrow CONFERENCE-AT-A-GLANCE 

PREMIER SPONSORS 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com